View in EDS

Cost‐effectiveness of contingency management for methamphetamine use disorder: A model‐based analysis.

Saved in:
Bibliographic Details
Title: Cost‐effectiveness of contingency management for methamphetamine use disorder: A model‐based analysis.
Authors: Qian, Gary L., Chen, Yupeng, Rawson, Richard A., Humphreys, Keith, Brandeau, Margaret L.
Source: Addiction. Aug2026, Vol. 121 Issue 8, p2127-2140. 14p.
Subjects: Substance abuse treatment, Substance abuse, Computer simulation, Quality-adjusted life years, Reinforcement (Psychology), Drug overdose, Mortality, Methamphetamine, Cardiovascular diseases, Research funding, Mental illness, Cost benefit analysis, Descriptive statistics, Contingency management, Medical care costs, Mental depression, Sensitivity & specificity (Statistics), Disease complications
Geographic Terms: United States
Abstract: Background and aims: The United States (US) is experiencing a surge in methamphetamine use. Treatment options for methamphetamine use disorder (MethUD) focus on behavior change, particularly via contingency management (CM), where individuals receive rewards for submitting drug‐free urine samples or for other positive behaviors such as attending treatment sessions. Little is known about the cost‐effectiveness of CM for treating MethUD, including the January 2025 decision by the US federal government to increase the maximum annual CM incentive ten‐fold to $750 per patient. This study aimed to assess the cost‐effectiveness of CM for individuals with MethUD in the US. Design, setting and participants: We developed a microsimulation model of methamphetamine use behavior among individuals with MethUD to assess the effectiveness and cost‐effectiveness of CM for treating MethUD. We modeled methamphetamine use states and psychiatric and cardiovascular comorbidities. We considered a 12‐week and 24‐week CM program, with a maximum $750 incentive. We simulated the model in weekly time steps over the lifetime of a cohort of 10 000 individuals with MethUD, under the status quo (no treatment) and with the CM program. Measurements: Number of deaths over one year and lifetime per person healthcare costs (healthcare sector perspective) and quality‐adjusted life years (QALYs) experienced. Findings With no treatment, 274 overdose deaths and 305 total deaths occurred in the cohort over 1 year. Individuals experienced 11.37 lifetime QALYs and incurred $216 320 in lifetime healthcare costs. With a 12‐week CM program, an estimated 117 deaths were prevented over 1 year, with a net gain of 0.70 lifetime QALYs per person and incremental cost of $6850 compared with no treatment, yielding an incremental cost‐effectiveness ratio (ICER) of $9830/QALY gained [95% credible interval (CR) = $8100–$11 400]. With a 24‐week program, 153 deaths were prevented over 1 year, with a net gain of 0.81 lifetime QALYs per person and incremental cost of $10 000, yielding an ICER of $12 312/QALY gained (95% CR = $10 400–$14 100). Even under the pessimistic assumption of no lasting behavior change after CM program completion, the programs cost less than $130 000/QALY gained. Threshold analysis suggests that at a $50 000 willingness to pay, the 24‐week program would be cost‐effective even if the maximum incentive were $2491. Conclusions: Modelling shows that contingency management appears to be a highly cost‐effective intervention for treating methamphetamine use disorder, even with conservative assumptions and a $750 incentive cap. When cost impacts in the criminal justice and child welfare systems are included, such programs are likely cost‐saving. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background and aims: The United States (US) is experiencing a surge in methamphetamine use. Treatment options for methamphetamine use disorder (MethUD) focus on behavior change, particularly via contingency management (CM), where individuals receive rewards for submitting drug‐free urine samples or for other positive behaviors such as attending treatment sessions. Little is known about the cost‐effectiveness of CM for treating MethUD, including the January 2025 decision by the US federal government to increase the maximum annual CM incentive ten‐fold to $750 per patient. This study aimed to assess the cost‐effectiveness of CM for individuals with MethUD in the US. Design, setting and participants: We developed a microsimulation model of methamphetamine use behavior among individuals with MethUD to assess the effectiveness and cost‐effectiveness of CM for treating MethUD. We modeled methamphetamine use states and psychiatric and cardiovascular comorbidities. We considered a 12‐week and 24‐week CM program, with a maximum $750 incentive. We simulated the model in weekly time steps over the lifetime of a cohort of 10 000 individuals with MethUD, under the status quo (no treatment) and with the CM program. Measurements: Number of deaths over one year and lifetime per person healthcare costs (healthcare sector perspective) and quality‐adjusted life years (QALYs) experienced. Findings With no treatment, 274 overdose deaths and 305 total deaths occurred in the cohort over 1 year. Individuals experienced 11.37 lifetime QALYs and incurred $216 320 in lifetime healthcare costs. With a 12‐week CM program, an estimated 117 deaths were prevented over 1 year, with a net gain of 0.70 lifetime QALYs per person and incremental cost of $6850 compared with no treatment, yielding an incremental cost‐effectiveness ratio (ICER) of $9830/QALY gained [95% credible interval (CR) = $8100–$11 400]. With a 24‐week program, 153 deaths were prevented over 1 year, with a net gain of 0.81 lifetime QALYs per person and incremental cost of $10 000, yielding an ICER of $12 312/QALY gained (95% CR = $10 400–$14 100). Even under the pessimistic assumption of no lasting behavior change after CM program completion, the programs cost less than $130 000/QALY gained. Threshold analysis suggests that at a $50 000 willingness to pay, the 24‐week program would be cost‐effective even if the maximum incentive were $2491. Conclusions: Modelling shows that contingency management appears to be a highly cost‐effective intervention for treating methamphetamine use disorder, even with conservative assumptions and a $750 incentive cap. When cost impacts in the criminal justice and child welfare systems are included, such programs are likely cost‐saving. [ABSTRACT FROM AUTHOR]
ISSN:09652140
DOI:10.1111/add.70377